Catch up on the developing stories making headlines.NEW YORK -- Drugmaker Pfizer, one of the leaders in the race to develop a COVID-19 vaccine, is tweaking its timeline for when it will know if its experimental two-dose vaccine works.
Analysts peppered Bourla and other Pfizer executives with so many questions about the study that he repeatedly asked for their patience.Pfizer said the final-stage trial has now enrolled nearly all of the planned participants. Nearly 36,000 had received their second shot as of Monday. The company could seek approval for emergency use from U.S. regulators in late November.
If it gets emergency use approval this year, Pfizer might have enough vaccine for about 15 million people. It's made hundreds of thousands of doses so far, banking on the vaccine being approved. The New York-based company on Tuesday said disruptions from the coronavirus pandemic reduced medicine sales in the U.S. and China by about $500 million. Still, Pfizer managed to top Wall Street expectations, and it raised and narrowed its profit forecasts slightly for all of 2020.